Effects of cholecystokinin-receptor blockade on pancreatic and biliary function in healthy volunteers.
This study used the specific cholecystokinin (CCK)-receptor antagonist loxiglumide to evaluate whether endogenous CCK, which is released after a meal, regulates pancreatic and biliary functions. Eight healthy volunteers were studied twice on separate days. The subjects received a continuous intraduodenal infusion of a 750-kcal liquid test meal for 2 hours either with or without IV infusion of 5 mg.kg-1.h-1 of loxiglumide. Loxiglumide at this dose abolishes the actions of CCK at various target organs including gallbladder and pancreas, when given at doses that mimic postprandial plasma concentrations of CCK. Loxiglumide markedly decreased the meal-stimulated outputs of amylase, trypsin, and chymotrypsin by 55%-70% of control values but only slightly decreased duodenal volume (25% inhibition of mean integrated secretion). Loxiglumide abolished gallbladder emptying induced by infusion of nutrients and even increased gallbladder volumes when compared with prior fasting values. Correspondingly, loxiglumide almost abolished the output of bilirubin after infusion of nutrients. However, loxiglumide failed to alter the increase in circulating concentrations of glucose, insulin, and C peptide after infusion of nutrients. The present results show that CCK is one of several factors that regulate pancreatic protein secretion after absorption of nutrients. However, CCK is probably not involved in regulation of pancreatic secretion of fluid. In contrast, gallbladder function is mainly regulated by CCK, both in terms of its emptying after intestinal absorption of nutrients and in terms of maintenance of its fasting volume. Cholecystokinin does not play a major physiological role as an insulinotropic factor.
Schwarzendrube
J
J
Medizinische Klinik und Poliklinik, Abteilung für Gastroenterologie, Heinrich-Heine-Universität, Düsseldorf, Germany.
Niederau
M
M
Lüthen
R
R
Niederau
C
C
D000328:Adult; D001663:Bilirubin / Q000378:metabolism; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000502:physiology*; D005260:Female; D005704:Gallbladder / Q000502:physiology*; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology; D008297:Male; D010179:Pancreas / Q000502:physiology*; D010189:Pancreatic Juice / Q000378:metabolism; D011377:Proglumide / Q000031:analogs & derivatives*; D011949:Receptors, Cholecystokinin / Q000187:drug effects*
D011949:Receptors, Cholecystokinin; C053737:loxiglumide; D002766:Cholecystokinin; D011377:Proglumide; D001663:Bilirubin